Expanding the use of hepatitis C-viremic kidney donors
- PMID: 29055420
- DOI: 10.1016/j.kint.2017.09.002
Expanding the use of hepatitis C-viremic kidney donors
Abstract
Direct-acting antivirals have revolutionized the treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease, with implications for the timing of antiviral treatment among kidney transplant candidates and for the use of HCV viremic donors. A recent consensus conference reviewed the available data on the safety and cost-effectiveness of expanding access to HCV-positive organs to HCV-negative recipients. Early trials are promising, but larger trials and a plan for obtaining HCV therapy in the posttransplantation period are needed. Implications for the larger transplant community also need to be considered.
Keywords: direct-acting antivirals; hepatitis c virus; kidney transplantation.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.Am J Transplant. 2017 Nov;17(11):2790-2802. doi: 10.1111/ajt.14381. Epub 2017 Jul 1. Am J Transplant. 2017. PMID: 28556422
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
